ANTX — AN2 Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $32.52m
- -$30.40m
- 23
- 52
- 92
- 57
Annual income statement for AN2 Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 7.28 | 21.6 | 42.3 | 69.6 | 56.8 |
| Operating Profit | -7.28 | -21.6 | -42.3 | -69.6 | -56.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13.6 | -21.5 | -41 | -64.7 | -51.3 |
| Net Income After Taxes | -13.6 | -21.5 | -41 | -64.7 | -51.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.6 | -21.5 | -41 | -64.7 | -51.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -14.6 | -28.1 | -42.8 | -64.7 | -51.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.778 | -1.5 | -2.79 | -2.74 | -1.65 |
| Dividends per Share |